Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupropion vs Escitalopram on Sexual Functioning in MDD
NCT00051259Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2003
- Primary completion
- Jun 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bupropion in major depressive disorder (MDD) (3 arms), sponsored by GSK. Primary endpoints: Percentage of subjects with orgasm dysfunction and Change in HAMD-17 total score. Started Jan 2003; status: completed.
02
Drugs
bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00051259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00051259.